Literature DB >> 27699608

Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy.

Yosuke Hirasawa1, Jun Nakashima2,3,4, Daisuke Yunaiyama5, Toru Sugihara2, Tatsuo Gondo2, Yoshihiro Nakagami2, Yutaka Horiguchi2, Yoshio Ohno2, Kazunori Namiki2, Makoto Ohori2, Koichi Tokuuye5, Masaaki Tachibana2.   

Abstract

PURPOSE: To investigate the prognostic significance of sarcopenia on long-term outcomes in patients with bladder cancer after radical cystectomy (RC).
METHODS: We retrospectively reviewed 136 patients undergoing RC for urothelial carcinoma at our institution. Prognostic impact of the preoperative clinical, laboratory, and radiologic parameters were evaluated by Cox proportional hazard model analyses, and a nomogram was developed to predict cancer-specific survival (CSS) after RC.
RESULTS: The mean follow-up was 46.7 months. Patients with sarcopenia had a significantly shorter CSS than those without sarcopenia. On univariate Cox analysis, clinical T stage, histology of transurethral resection of bladder tumor (TURBT) specimen, pretreatment hemoglobin, pretreatment neutrophil-to-lymphocyte ratio (NLR), pretreatment serum C-reactive protein level, pretreatment serum albumin level, presence of hydronephrosis, and presence of sarcopenia were associated with significantly worse CSS. On multivariate Cox stepwise analysis, sarcopenia (hazard rate [HR] = 2.3, p = 0.015), clinical T stage (cT4: HR = 5.3; p = 0.0096), presence of hydronephrosis (HR = 2.0; p = 0.033), histology of TURBT specimen (HR = 2.2, p = 0.044), and NLR (HR = 1.3; p = 0.0048) were significant independent predictors of an unfavorable prognosis Based on the results of the multivariate analysis, we developed a nomogram to predict 1-, 3-, and 5-year CSS after RC.
CONCLUSIONS: Sarcopenia, clinical T stage, presence of hydronephrosis, histology of TURBT specimen, and NLR are novel preoperative prognostic factors even after adjustment for other known preoperative predictors in patients undergoing RC for bladder cancer.

Entities:  

Mesh:

Year:  2016        PMID: 27699608     DOI: 10.1245/s10434-016-5606-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  28 in total

1.  The prognostic role of preoperative circulating neutrophil-lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis.

Authors:  Guoming Hu; Feng Xu; Kefang Zhong; Shimin Wang; Qi Xu; Liming Huang; Pu Cheng
Journal:  World J Urol       Date:  2018-12-03       Impact factor: 4.226

2.  The clinical use of neutrophil-to-lymphocyte ratio in bladder cancer patients: a systematic review and meta-analysis.

Authors:  Xingxing Tang; Peng Du; Yong Yang
Journal:  Int J Clin Oncol       Date:  2017-07-27       Impact factor: 3.402

3.  Loss of skeletal muscle mass after curative gastrectomy is a poor prognostic factor.

Authors:  Naruji Kugimiya; Eijiro Harada; Kazuhito Oka; Daichi Kawamura; Yuki Suehiro; Yoshihiro Takemoto; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

4.  Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer.

Authors:  Roman Mayr; Hans-Martin Fritsche; Florian Zeman; Marieke Reiffen; Leopold Siebertz; Christoph Niessen; Armin Pycha; Bas W G van Rhijn; Maximilian Burger; Michael Gierth
Journal:  World J Urol       Date:  2018-03-08       Impact factor: 4.226

5.  Implementing a Multimodal Prehabilitation Program to Radical Cystectomy in a Comprehensive Cancer Center: A Pilot Study to Assess Feasibility and Outcomes.

Authors:  Bente Thoft Jensen; Jørgen B Jensen; Nora Love-Retinger; Mallory Bowker; Caitlyn Retinger; Guido Dalbagni
Journal:  Urol Nurs       Date:  2019 Nov-Dec

6.  The impact of preoperative nutritional status on post-surgical complication and mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review of the literature.

Authors:  Paola Irene Ornaghi; Luca Afferi; Alessandro Antonelli; Maria Angela Cerruto; Katia Odorizzi; Alessandra Gozzo; Livio Mordasini; Agostino Mattei; Philipp Baumeister; Julian Cornelius; Alessandro Tafuri; Marco Moschini
Journal:  World J Urol       Date:  2020-06-09       Impact factor: 4.226

Review 7.  [Limits of surgery in uro-oncology].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

Review 8.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

9.  Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.

Authors:  Tetsuya Yumioka; Masashi Honda; Ryoma Nishikawa; Shogo Teraoka; Yusuke Kimura; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2019-09-13       Impact factor: 3.402

10.  Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy.

Authors:  Ryutaro Shimizu; Masashi Honda; Shogo Teraoka; Tetsuya Yumioka; Noriya Yamaguchi; Bunya Kawamoto; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2021-10-04       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.